Definium Therapeutics, Inc. (FRA:MMQ0)

Germany flag Germany · Delayed Price · Currency is EUR
14.20
+0.55 (4.03%)
At close: Jan 30, 2026
100.99%
Market Cap1.40B +190.5%
Revenue (ttm)n/a
Net Income-143.27M
EPS-1.68
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume129
Open14.20
Previous Close13.65
Day's Range14.20 - 14.20
52-Week Range4.29 - 14.95
Betan/a
RSI63.65
Earnings DateMar 5, 2026

About Definium Therapeutics

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to... [Read more]

Industry Pharmaceutical Preparations
Founded 2019
Employees 74
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol MMQ0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements